Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board
“Surface Oncology continues to grow and learn as a company and we look to align ourselves with world-class leaders in the fields of oncology and immunology. Steve is a clinical pioneer in the field of cancer immunotherapy. His groundbreaking work in melanoma with checkpoint inhibitors led to the first wave of cancer immunotherapy drug approvals. We are thrilled Steve has agreed to join our world-class scientific advisory board and look forward to his clinical and scientific insights,” said Vito Palombella PhD, chief scientific officer of Surface Oncology.
Dr. Hodi is Director of the Melanoma Center and the
“I am excited to have the opportunity to collaborate with the team at
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
For more information, please visit www.surfaceoncology.com
Source: Surface Oncology, Inc.